Eiger Corporate News

»Eiger Corporate News
29 08, 2019

Eiger BioPharmaceuticals to Participate in September Conferences

2019-08-29T20:16:25+00:00

Eiger BioPharmaceuticals to Participate in September Conferences PALO ALTO, Calif. – August 29, 2019 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that management will participate in the following upcoming investor conferences in September: Baird 2019 Global Healthcare Conference at the [...]

Eiger BioPharmaceuticals to Participate in September Conferences2019-08-29T20:16:25+00:00
17 06, 2019

Eiger Announces Breakthrough Therapy Designation Granted by FDA for Avexitide for Treatment of Post-Bariatric Hypoglycemia (PBH)

2019-06-17T20:57:19+00:00

Eiger Announces Breakthrough Therapy Designation Granted by FDA for Avexitide for Treatment of Post-Bariatric Hypoglycemia (PBH) Third Eiger Pipeline Program Granted Breakthrough Therapy Designation PALO ALTO, Calif., June 17, 2019 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced that the Food [...]

Eiger Announces Breakthrough Therapy Designation Granted by FDA for Avexitide for Treatment of Post-Bariatric Hypoglycemia (PBH)2019-06-17T20:57:19+00:00
10 06, 2019

Eiger Appoints Industry Veteran and Regulatory Affairs Expert Mark Mannebach, PhD, RPh as Vice President of Global Regulatory Affairs

2019-06-10T13:59:43+00:00

Eiger Appoints Industry Veteran and Regulatory Affairs Expert Mark Mannebach, PhD, RPh as Vice President of Global Regulatory Affairs PALO ALTO, Calif., June 10, 2019 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare and ultra-rare diseases, today announced the appointment of Mark Mannebach, PhD, RPh as Vice President [...]

Eiger Appoints Industry Veteran and Regulatory Affairs Expert Mark Mannebach, PhD, RPh as Vice President of Global Regulatory Affairs2019-06-10T13:59:43+00:00
17 05, 2019

Eiger BioPharmaceuticals Announces Transition of Chief Operating Officer and Executive Medical Officer

2019-05-17T20:53:43+00:00

Eiger BioPharmaceuticals Announces Transition of Chief Operating Officer and Executive Medical Officer PALO ALTO, Calif., May 17, 2019 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Apelian will step down as the Company’s Chief Operating Officer and Executive Medical [...]

Eiger BioPharmaceuticals Announces Transition of Chief Operating Officer and Executive Medical Officer2019-05-17T20:53:43+00:00
9 05, 2019

Eiger BioPharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update

2019-05-09T20:50:39+00:00

Eiger BioPharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update First-Ever Phase 3 HDV International “D-LIVR” Study UnderwayNDA and MAA filings for Progeria & Progeroid Laminopathies planned in 2019Strong Balance Sheet with Recent Financing CompletedPALO ALTO, Calif., May 9, 2019 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted [...]

Eiger BioPharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update2019-05-09T20:50:39+00:00
15 04, 2019

Eiger BioPharmaceuticals Appoints Market Access, Public Policy Expert, and Biotech Veteran Amit K. Sachdev to Board of Directors

2019-04-15T12:26:41+00:00

Eiger BioPharmaceuticals Appoints Market Access, Public Policy Expert, and Biotech Veteran Amit K. Sachdev to Board of Directors PALO ALTO, Calif., April 15, 2019 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for serious rare and ultra-rare diseases, announced today the appointment of Amit K. Sachdev, JD to its Board [...]

Eiger BioPharmaceuticals Appoints Market Access, Public Policy Expert, and Biotech Veteran Amit K. Sachdev to Board of Directors2019-04-15T12:26:41+00:00
14 03, 2019

Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

2019-03-14T22:50:48+00:00

Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update Began 2019 with $100.4 million in cash, cash equivalents & short-term investmentsEnrollment of Phase 3 D-LIVR Study in HDV planned by end of 2019NDA and MAA filings for Progeria and Progeroid Laminopathies planned in 2019 PALO ALTO, Calif., March 14, 2019 [...]

Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update2019-03-14T22:50:48+00:00
27 02, 2019

Eiger BioPharmaceuticals Announces the Appointment of Stephana Patton as General Counsel, Corporate Secretary, and Chief Compliance Officer

2019-02-27T14:57:39+00:00

Eiger BioPharmaceuticals Announces the Appointment of Stephana Patton as General Counsel, Corporate Secretary, and Chief Compliance Officer PALO ALTO, Calif., February 27, 2019 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced the appointment of Dr. Stephana Patton as the Company’s General [...]

Eiger BioPharmaceuticals Announces the Appointment of Stephana Patton as General Counsel, Corporate Secretary, and Chief Compliance Officer2019-02-27T14:57:39+00:00
7 01, 2019

Eiger BioPharmaceuticals Appoints Regulatory Expert and Industry Veteran Christine Murray, MS, RAC to its Board of Directors

2019-01-07T15:50:15+00:00

Eiger BioPharmaceuticals Appoints Regulatory Expert and Industry Veteran Christine Murray, MS, RAC to its Board of Directors PALO ALTO, Calif., January 7, 2019 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare and ultra-rare diseases, announced today the appointment of Christine Murray, MS, RAC to its Board of Directors. [...]

Eiger BioPharmaceuticals Appoints Regulatory Expert and Industry Veteran Christine Murray, MS, RAC to its Board of Directors2019-01-07T15:50:15+00:00
11 12, 2018

Eiger BioPharmaceuticals Reports on 2018 R&D Day

2018-12-11T21:30:44+00:00

Eiger BioPharmaceuticals Reports on 2018 R&D Day Late Stage Rare and Ultra-Rare Disease Pipeline Advancing >$100M in Cash Available to Achieve Key Milestones PALO ALTO, Calif., December 11, 2018 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced recent accomplishments reported at [...]

Eiger BioPharmaceuticals Reports on 2018 R&D Day2018-12-11T21:30:44+00:00